Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used for primary staging in prostate cancer (PC), mainly because of its improved accuracy in detecting lymph node metastases compared with conventional imaging. Here, FOLH1 is linked to metastatic malignant neoplasm in the lymph nodes.